Members Only Content
Subscribe to get full access
Free Preview
This is the decade synthetic biology becomes real. Investors need new frameworks to keep up. 7investing Lead Advisor Maxx Chatsko nerds out with Stanford University's Drew Endy to discuss what's ahead for synthetic biology.
Upstart Recommendation Report Upstart Presentation Slides
Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]
PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]
